To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:2 Issue:9 Number:31 ISSN#:2564-2537
Author Verified
ACE Report #5101
Ace Report Cover Tumour

Osteosarcoma: methotrexate & doxorubicin versus methotrexate, etoposide & ifosfamide

How to Cite

OrthoEvidence. Osteosarcoma: methotrexate & doxorubicin versus methotrexate, etoposide & ifosfamide. ACE Report. 2013;2(9):31. Available from:

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients

Eur J Cancer. 2007 Mar;43(4):752-61. Epub 2007 Jan 30

Contributing Authors:
MC Le Deley JM Guinebretiere JC Gentet H Pacquement F Pichon P Marec-Berard N Entz-Werle C Schmitt L Brugieres D Vanel N Dupouy MD Tabone C Kalifa (SFOP) Societe Francaise d'Oncologie Pediatrique

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


234 patients with nonmetastatic osteosarcoma were randomized to preoperative chemotherapy of high-dose methotrexate with either doxorubicin or with etoposide and ifosfamide. After a median of 77-month follow-up, patients who had received the etoposide-ifosfamide regimen exhibited a larger percentage of good histologic response. Three- and 5-year overall and event-free survival rates were significa...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.